The Pharmaceutical Committee of the American Chamber of Commerce in the Netherlands (AmCham) voices its concerns about the investment climate for pharmaceutical companies in the Netherlands. The medicines policy that has been initiated increasingly undermines the very basis that companies need to develop and market new medicines. AmCham therefore calls for a medicines policy that keeps the Netherlands an attractive investment location for pharmaceutical companies. Read more...
